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Abstract
Word count : 259
 
Pat ient s wit h visceral  leishmaniasis (VL) – human immunodef iciency virus (HIV) coinfect ion experience increased drug t oxici t y and
t reat ment  fai lure rat es compared t o VL pat ient s,  wit h more f requent  VL relapse and deat h.  In t he era of  VL el iminat ion
st rat egies,  HIV coinfect ion is progressively becoming a key chal lenge,  because HIV coinfect ed pat ient s respond poorly t o
convent ional  VL t reat ment  and play an import ant  role in parasit e t ransmission.  Wit h l imit ed chemot herapeut ic opt ions and a
paucit y of  novel  ant i-parasit ic drugs,  new int ervent ions t hat  t arget  host  immunit y may of fer an ef fect ive al t ernat ive.  In t his
review,  we f i rst  summarize current  views on how VL immunopat hology is signif icant ly af fect ed by HIV coinfect ion.  We t hen
review current  cl inical  and promising precl inical  immunomodulat ory int ervent ions in t he f ield of  VL and discuss how t hese may
operat e in t he cont ext  of  a concurrent  HIV infect ion.  Caveat s are formulat ed as t hese int ervent ions may unpredict ably impact  t he
del icat e balance bet ween boost ing of  benef icial  VL-specif ic responses and delet erious immune act ivat ion/ hyperinf lammat ion,
act ivat ion of  lat ent  provirus or increased HIV-suscept ibi l i t y of  t arget  cel ls.  Evidence is lacking t o priori t ize a t arget  molecule and a
more det ai led account  of  t he immunological  st at us induced by t he coinfect ion as wel l  as surrogat e markers of  cure and prot ect ion
are st i l l  required.  We do however argue t hat  vi rological ly suppressed VL pat ient s wit h a recovered immune syst em,  in whom
ef fect ive ant i ret roviral  t herapy alone is not  able t o rest ore prot ect ive immunit y,  can be considered a relevant  t arget  group for
an immunomodulat ory int ervent ion.  Final ly,  we provide perspect ives on t he t ranslat ion of  novel  t heories on synergist ic immune
cel l  cross-t alk int o an ef fect ive t reat ment  st rat egy for VL-HIV coinfect ed pat ient s.
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Abstract 28 
Patients with visceral leishmaniasis (VL) ± human immunodeficiency virus (HIV) coinfection 29 
experience increased drug toxicity and treatment failure rates compared to VL patients, with 30 
more frequent VL relapse and death. In the era of VL elimination strategies, HIV coinfection 31 
is progressively becoming a key challenge, because HIV coinfected patients respond poorly to 32 
conventional VL treatment and play an important role in parasite transmission. With limited 33 
chemotherapeutic options and a paucity of novel anti-parasitic drugs, new interventions that 34 
target host immunity may offer an effective alternative. In this review, we first summarize 35 
current views on how VL immunopathology is significantly affected by HIV coinfection. We 36 
then review current clinical and promising preclinical immunomodulatory interventions in the 37 
field of VL and discuss how these may operate in the context of a concurrent HIV infection. 38 
Caveats are formulated as these interventions may unpredictably impact the delicate balance 39 
between boosting of beneficial VL-specific responses and deleterious immune 40 
activation/hyperinflammation, activation of latent provirus or increased HIV-susceptibility of 41 
target cells. Evidence is lacking to prioritize a target molecule and a more detailed account of 42 
the immunological status induced by the coinfection as well as surrogate markers of cure and 43 
protection are still required. We do, however, argue that virologically suppressed VL patients 44 
with a recovered immune system, in whom effective antiretroviral therapy alone is not able to 45 
restore protective immunity, can be considered a relevant target group for an 46 
immunomodulatory intervention. Finally, we provide perspectives on the translation of novel 47 
theories on synergistic immune cell cross-talk into an effective treatment strategy for VL-HIV 48 
coinfected patients.   49 
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1. Introduction 50 
Visceral leishmaniasis (VL), also called kala-azar, is a vector-borne protozoan infection 51 
caused by species of the Leishmania donovani complex, which mainly targets tissue 52 
macrophages of systemic organs, such as spleen, liver and bone marrow (1). Characteristics of 53 
the disease include chronic fever, hepatosplenomegaly, and pancytopenia (1). Untreated, overt 54 
disease is universally lethal (1). Zoonotic VL, with dogs as the main reservoir, is mainly 55 
prevalent in the Mediterranean basin and in South America, and is caused by Leishmania (L.)  56 
infantum. Anthroponotic VL is prevalent on the Indian subcontinent and in East Africa and is 57 
typically caused by L. donovani (2). According to the recent World Health Organization 58 
(WHO) report, VL is endemic in 75 countries with an estimated 50,000 to 90,000 new cases 59 
occurring each year (3). Ninety percent of the global disease burden occurs in just six 60 
countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia (3). 61 
 62 
Chemotherapy is currently the sole form of treatment in clinical practice. The pentavalent 63 
antimonial (SbV) compounds (sodium stibogluconate (SSG) commercialized as Pentostam®; 64 
meglumine antimoniate commercialized as Glucantime®) have been the cornerstone of first-65 
line treatment of VL over the last 70 years. However, these compounds, but are far from 66 
optimal due to severe toxicity and the emergence of antimonial resistance on the Indian 67 
subcontinent (1, 4). Newer drugs that are increasingly used include paromomycin, 68 
miltefosine, pentamidine, and conventional and liposomal amphotericin B. All these drugs 69 
have  a number of importantseveral important disadvantages as shown in  (Table 1). While 70 
various combination therapy regimens designed to overcome some of the shortcomings are 71 
highly efficacious in India, disappointing findings on some combination regimens have been 72 
recently reported in East Africa  (5-10). As of Until today, no comparative studies have been 73 
conducted done to explain this geographical difference, but the parasite genetic diversity 74 
diverse parasite species and host immune phenotypesity genotypes are assumed as key 75 
factors. Novel chemotherapeutic drugs are in the initial development pipeline and but are 76 
therefore unlikely to be widely available within the next few years. Nevertheless, over 90% to 77 
95% of immunocompetent patients display a good clinical response to currently 78 
recommended conventional treatment regimens, with treatment unresponsiveness, death or 79 
severe toxicity observedseen in less than 5% to 10% of patients (11). Less than 5% of 80 
immunocompetent individuals who initially cure develop a relapse, most commonly within 6-81 
12 months after treatment (5). Treatment outcomes however vary substantially between 82 
different geographic regions and depend on the drug(s) used, drug exposure, parasite 83 
susceptibility to the drug, severity of disease, host immunity and the presence of coinfections 84 
(11-13). 85 
1.1. Emerging challenge of VL-HIV coinfection 86 
Human immunodeficiency virus (HIV) has been identified as one of the emerging challenges 87 
facing the control of VL (14). The immunological status of HIV-infected patients is 88 
particularly favorable for the multiplication of Leishmania parasites. HIV coinfection 89 
substantially increases the risk of progression from asymptomatic Leishmania infection to 90 
active disease (15, 16). On the other hand, VL accelerates HIV disease progression towards 91 
acquired immunodeficiency syndrome (AIDS) and could induce expression of latent 92 
proviruses (14). HIV has fueled the re-emergence of VL in Southern Europe and Brazil, 93 
where up to 70% of VL cases are associated with HIV infection (7). Tand the problem is 94 
currently particularly severe in areas such as Northern Ethiopia, where up to 430% of all 95 
patients with VL patients are coinfected with HIV (17). Since 2001, 35 countries have 96 
reported between 2 to 30% of VL cases as co-infected with HIV, but thisese percentagess 97 
isare most probably underestimations (14). Because the disease affects the most poor and 98 
most neglected patients within an already neglected disease population, under-reporting in 99 
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most endemic areas is common due to a lack of facilities to diagnose one or both of the 100 
diseases and to poor reporting systems. Importantly, VL-HIV coinfected patients are also 101 
often considered super-spreaders of VL, and thus pose a major threat to current elimination 102 
strategies (18). 103 
 104 
Since 1996, combined antiretroviral treatment (cART), comprising three antiretroviral drugs, 105 
constitutes the cornerstone of HIV treatment. The treatment options continue to expand with 106 
new drugs and co-formulations; by the end of 2016, there were 40 antiretroviral drugs from 107 
six different classes approved by the Food and Drug Administration. In most resource-108 
constrained settings, the standardized WHO guidelines are used for ART, which currently 109 
recommends a combination of tenofovir, lamivudine and efavirenz as first line treatment. 110 
WHO recommended first line regimens have been found highly effective in resource-111 
constrained settings (19). The main aim of cART is sustainabledurable suppression of HIV 112 
replication, and with good adherence, this can generally be achieved, leading to a close to 113 
normal life expectancy (20).  114 
 115 
VL is one of the AIDS-defining conditions, requiring anti-leishmanial treatment and cART 116 
irrespective of CD4+ T cell count (7). Although there are limited in vitro data suggesting that 117 
HIV-1 protease inhibitors and possibly some other antiretroviral drugs might directly exert 118 
inhibitory effects on Leishmania, there is insufficient evidence for their clinical use against 119 
VL, and standard ART regimens are currently recommended in VL-HIV coinfection (5). In 120 
low income countries, this is provided by standardized first and second line regimens in a 121 
public health approach (21, 22).  122 
 123 
Increased toxicity and parasitologically-confirmed treatment failures (up to 30%) were 124 
observed in VL-HIV coinfected patients treated with SbV, with case fatality rates up to 24% 125 
(14, 17, 23). While liposomal amphotericin B was consistently found to have excellent 126 
tolerability, VL cure rates in HIV coinfected individuals have been rather disappointing in 127 
East Africa. For example, at a total dose of 30 mg/kg, around 16% of primary VL and 56% of 128 
VL relapse cases demonstrate parasitological failure in northern Ethiopia (17). WHO now 129 
proposes a total dose of 40 mg/kg (7, 24, 25). Experience with miltefosine in VL-HIV 130 
coinfection is limited, but suggests moderate efficacy and an acceptable toxicity profile (23, 131 
26-29). To date, only one clinical trial in HIV coinfected patients has been conducted with 132 
miltefosine, with 18% of patients displaying initial parasitological treatment failure and 25% 133 
relapsing, although deaths were excluded (23). The role of combination therapy in VL-HIV 134 
coinfection is currently under exploration in clinical trials in India and East-Africa. 135 
 136 
While in Europe widespread use of cART has resulted in a pronounced (i.e. 60 %) reduction 137 
in the incidence of VL-HIV coinfection, relapse in coinfected subjects remains substantial at 138 
up to 60% after one year (14, 30, 31) and secondary prophylaxis has only a partial effect (32). 139 
In a pentamidine secondary prophylaxis trial in Ethiopia, the relapse-free survival rate at two 140 
years was only 58.3% (Diro 2017, CID, in press). Even with access to all current 141 
chemotherapies, the prognosis in VL-HIV coinfection remains dire. Currently, it is believed 142 
that VL can only be effectively treated in HIV patients before profound immune deficiency 143 
has developed.  144 
 145 
VL-HIV coinfection has a number of unique clinical and immunological features. In contrast 146 
to many other HIV-associated opportunistic infections, CD4+ T cell reconstitution is severely 147 
delayed (even if virological suppression is reached) and the immune reconstitution 148 
inflammatory syndrome (IRIS) to a Leishmania infection after initiation of cART appears 149 
relatively rare, indicating a persistent suppression of host immunity (33, 34). Atypical clinical 150 
presentations can occur and amastigotes have been detected in tissues such as the intestine, 151 
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where parasites are mostly undetectable in the immunocompetent host (14, 35). After clinical 152 
remission, parasitemia also appears to persist, at least intermittently (36). A 153 
FKURQLFLQWHUPLWWHQWFRXUVHRI9/ODVWLQJVHYHUDO\HDUVKDVEHHQGHVFULEHGODEHOOHGDV³DFWLYH 154 
FKURQLF YLVFHUDO OHLVKPDQLDVLV´ (36). Consequently, HIV-infected patients will develop 155 
multiple VL relapses and often become progressively more difficult to treat, ultimately 156 
leading to a stage of complete treatment unresponsiveness. Hence, there is an urgent need for 157 
innovative and effective alternative therapies against VL-HIV coinfection. 158 
1.2. Promising role of immunomodulatory therapy 159 
It has become increasingly clear that the host immune response is a critical factor determining 160 
VL treatment response and control, acting in synergy with anti-leishmanial drugs (37). This 161 
implies that in immunosuppressed individuals, targeting parasites alone with conventional 162 
anti-leishmanial drugs but without enhancing the immune response might simply not be 163 
sufficient. This interaction between drugs and the immune system was first suggested in 164 
animal models of VL, where the efficacy of pentavalent antimony (Sbv) was lower after T cell 165 
depletion (38). This was, probably related to the decreased cellular uptake of SbV into 166 
interferon gamma (,)1Ȗ) activated macrophages, where it is normally converted 167 
intracellularly into its active trivalent form (SbIII) (4). While this finding should be 168 
extrapolated with caution, this mechanism may explain the observations that 169 
immunocompromised patients with VL failed to respond to antimonial drugs. 170 
 171 
Immunotherapy is defined as the use of biological molecules or pharmacological compounds 172 
to modulate immune responses directly or in combination with drugs. A combination of 173 
immunomodulatory and direct anti-parasitic drugs could enhance the efficacy of 174 
chemotherapy and even prevent drug resistance (39). On top of its successful use in treating 175 
several non-infectious disorders (e.g. cancer, rheumatoid arthritis, etc.), the use of immune-176 
based combination therapy is increasingly being explored in infectious diseases such as 177 
tuberculosis (40) and leprosy (41)has proven successful in malaria, tuberculosis and leprosy. 178 
Despite several candidates being in the drug development pipeline, there are no 179 
immunotherapeutic agents or vaccines against VL currently registered for human use in 180 
routine clinical practice due to multiple reasons (e.g. high costs of clinical trials, limited and 181 
remote patient populations, ineffectiveness, safety concerns, etc.) (42). Experimental immune-182 
based approaches are also being explored in the domain of HIV, where many have reached 183 
Phase I and some Phase II clinical trials but as of until today have failed to provide enough 184 
immune restoration, potent effectiveness, sustainable benefits, delay of clinical progression or 185 
good safety profiles  (40, 43-46). However, VL-HIV coinfected patients are often excluded or 186 
neglected in such studies, although both individual patients as well as public health 187 
approaches in general could benefit from these interventions. 188 
 189 
Here, we first summarize current views on how host immunity against VL is affected during 190 
HIV coinfection, and then discuss the potential of current immunomodulatory therapies 191 
against VL in the context of concurrent HIV infection (both human studies and promising 192 
experimental approaches, excluding prophylactic studies). In particular, key targets and 193 
potential caveats are emphasized to guide future research on immunomodulatory therapies 194 
against VL and support the inclusion of HIV coinfected patients in clinical research. 195 
2. Immunopathogenesis of VL-HIV coinfection 196 
Macrophages represent an important common reservoir for HIV and Leishmania and serve as 197 
vehicles that disseminate both virus and parasite throughout the host. In addition, both 198 
pathogens may interact with each other to exacerbate immune suppression (Figure 1). In fact, 199 
both pathogens severely alter the antigen processing and presentation capacities of dendritic 200 
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cells and macrophages, and synergistically escape immune surveillance using an array of 201 
strategies yet to be fully understood (47). 202 
 203 
The control of VL in experimental models has been robustly associated with a strong T helper 204 
1 (Th1) immune response, with large amounts of IL-2 and IFNȖ (48) (Figure 1). In addition, a 205 
M2 polarization of macrophages has been associated with suppression of cell-mediated 206 
immunity, that confers susceptibility to intracellular infection. However, the immune 207 
mechanisms modulating VL in murine models or humans differs significantly. Human studies 208 
have shown a Th1/Th17 protective pattern with a somewhat different T cell functionality 209 
compared to experimental models, but lack comprehensive longitudinal data (49, 50). CD8+ T 210 
cells have also been shown to produce IFNȖ that can contribute to VL control (51). The 211 
immunosuppressive effects of IL-10, and the regulatory role of other cytokines such as IL-27, 212 
have been implicated in the development of the different clinical pictures (50). Impaired 213 
neutrophil effector function has also been suggested to play a key role in the pathogenesis of 214 
VL (52). Partly due to the lack of good animal or in vitro models, it is currently unknown 215 
whether and how these protective and immunosuppressive patterns of VL are modulated by 216 
HIV and ART and how they define the pertinent clinical outcomes of VL-HIV patients. 217 
 218 
HIV-1 causes a general profound impairment of cell-mediated immunity with low levels of 219 
CD4+ Th1 cells, the main protective cells in VL (Figure 1). HIV also skews the host immunity 220 
towards a Th2 response that only becomes affected at the later stages of the viral infection, 221 
potentially provoking parasite replication. Th17 cells are also associated with protection in 222 
The o VL, andbut are  protection-associated T-helper subset of Th17 cells are is highly 223 
permissive to HIV infection., Tand t and their frequency is significantly and preferentially 224 
reduced in the gastrointestinal tract, even in patients with undetectable plasma viral load 225 
under ART (53). DTheir depletion of Th17 cells from the gut- associated lymphoid tissue 226 
together with a series of immunopathological events occurring at the gastrointestinal tract 227 
mucosa leads to microbial translocation and consequently higher non-specific immune 228 
activation and hyper-inflammation (54). This microbial translocation has been postulated as 229 
one of the factors causing non-specific early T cell exhaustion and senescence (55), which 230 
may further weaken protective immunity towards VL. Likewise, VL was reported as an 231 
independent cause of increased non-specific immune activation, T cell senescence and the 232 
lack of immune recovery in virologically-suppressed coinfected HIV patients (56, 57). In line 233 
with T cell exhaustion, chronic immune activation was recently associated with recurrent 234 
relapse of VL in HIV patients (58). Recent research in VL-HIV patients also suggested that 235 
weak antigen-specific functional responses or proliferation of T cells after in vitro stimulation 236 
was an important predictor of relapse (59). Despite the pivotal role of CD8+ T cells in viral 237 
and parasite clearance, their contribution in VL-HIV control and level of exhaustion remains 238 
unknown. Likewise, it is still unclear as to what impact Leishmania infection could have on 239 
the capacity of resting memory CD4+ T cells to act as a stable reservoir of latent HIV 240 
infection,. WVor vice versa, it remains unknown what impact a spike in viral replication may 241 
have on anti-leishmanial immunity (e.g. by bystander activation of Leishmania specific 242 
memory cells) also remains unknown (60, 61). 243 
 244 
The consequences of infection by two immune suppressive pathogens could therefore be a 245 
symbiotic and SHUVLVWHQW LQFDSDFLWDWLRQ RI WKH KRVW¶V LPPXQH V\VWHP favoring a state of 246 
immunological anergy, ultimately being fatal to the patient. A better understanding of the 247 
immune response against Leishmania infection in HIV coinfected patients is crucial to 248 
establish a rational approach for immunomodulatory therapy. 249 
3. Status of immunotherapeutic interventions in human VL and their application in 250 
HIV patients 251 
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Due to the lack of a protective role of anti-Leishmania antibodies in early studies, passive 252 
immunization was not further explored, while active immunization with immunomodulators 253 
and vaccine therapy was investigated (62). Early studies by Murray et al. (38, 63, 64)showed 254 
the therapeutic utility of interleukin-2 (IL-2), IL-12, interferon-gamma (IFNȖ) and 255 
granulocyte-monocyte colony stimulating factor (GM-CSF) in murine VL models (38, 63, 256 
64). Although the Th1/Th2 dichotomy of immunity to VL is not fully upheld in humans, 257 
clinical immunotherapeutic studies on VL patients have been skewed towards Th1-associated 258 
cytokine adjuvanted therapy and are discussed below (see Table 2). For VL-HIV coinfection, 259 
only five published case reports using recombinant ,)1Ȗ, IL-2 and GM-CSF combined 260 
chemotherapy were found in literature (see Table 2).  261 
3.1. Interferon-Ȗy (IFNȖy) 262 
There has been limited success in small-scale clinical trialVZLWKFRPELQHG WKHUDS\RI ,)1Ȗ 263 
and SbV for treating VL. This combination therapy displayed stronger parasitological and 264 
clinical cure rates in VL patients (mainly children) from Brazil, Kenya and India compared 265 
with the drug alone, but these studies had several limitations (see Table 2 for details). In a 266 
subsequent larger randomized controlled trial (RCT) in India, these improved treatment 267 
outcomes could not be confirmed (65). Importantly, treatment response in this particular study 268 
was generally poor as drug resistance was emerging in that region.  269 
 270 
There are a few case reports, mostly from the pre-ART eraarea, providing information on 271 
whether IFNȖ FDQ EH VDIHO\ administered in VL-HIV patients (see Table 2), which is of 272 
relevance since IFNȖ DOVR KDV D vital but ambiguous role in the pathogenesis of HIV (66). 273 
IFNȖ appeared to be fairly well tolerated but showed inconclusive results (67-69). In one old 274 
case report of a patient with VL-HIV coinfection, DFFHOHUDWLRQRI.DSRVL¶Vsarcoma has been 275 
reported (70). The therapeutic potential of IFNȖWRWUHDW+,9coinfections, was supported by 276 
two Phase II trials, evaluating adjunctive IFNȖWRLPSURYHWUHDWPHQWUHVSRQVHWRDQWLIXQJDOVLQ277 
HIV patients with cryptococcal meningitis (71, 72). However, in the early 1990s, a 278 
multicenter clinical trial of SSG plus IFNȖ IRUVL in HIV coinfected patients in Spain was 279 
suspended following an interim analysis indicating that there was an excess of severe 280 
secondary effects and no benefit over drug alone (69). The findings itself have never been 281 
published but  suggested  a limited value of IFNȖ therapy for VL-HIV coinfection.  282 
3.2. Granulocyte macrophage colony stimulating factor (GM-CSF)  283 
GM-CSF can inhibit the intracellular replication of protozoa such as Leishmania. The 284 
justification to explore GM-CSF as immunotherapeutic agent stems from documented effects 285 
such as monocyte mobilization, macrophage activation, the production of pro-inflammatory 286 
cytokines and amelioration of neutropenia (63). GM-CSF combined with SbV was 287 
successfully explored in 20 neutropenic VL patients in Brazil. All responded well to VL 288 
treatment, neutropenia rapidly improved and secondary infections decreased (73) (Table 2). 289 
The authors did however not include a control arm, however, making it unclear whether the 290 
effect of GM-CSF, if any, could be due to the reversal of neutropenia (and might hence not 291 
apply in those without neutropenia) or whether other mechanisms were involved. On the other 292 
hand, in vitro studies have recently suggested that GM-CSF could contradictory promote 293 
Leishmania growth by inducing monocyte proliferation and induction of intracellular dNTP 294 
production (74), but whether this would also occur in humans remains unknown.  295 
 296 
In terms of safety, several older clinical trials of GM-CSF administration in HIV patients 297 
indicated that it might accelerate HIV replication (75). In contrast, more recent RCTs have 298 
demonstrated benefits of using GM-CSF in virologically suppressed patients as an adjunct to 299 
conventional ART or therapeutic HIV vaccination (75, 76). This would argue against using 300 
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GM-CSF in pre-ART patients, but might suggest it to be safe in those stable on ART. With 301 
regard to coinfections, some case reports were published on successful GM-CSF therapy of 302 
resistant-to-standard-therapy mycobacterial infection and pulmonary aspergillosis in HIV 303 
patients (77, 78). There is a single successful case report on immunotherapy targeting primary 304 
VL in an Italian AIDS patient, whereby human GM-CSF was combined with liposomal 305 
amphotericin B (Table 2) (79). Presently the evidence for beneficial effects of GM-CSF on 306 
HIV disease is limited, but GM-GSF adjuvanted therapy could provide a potential value for 307 
treatment of neutropenic VL in stable ART patients. 308 
3.3. Interleukin-2 (IL-2) 309 
IL-2 induces clonal expansion of specific T cells, promotes natural killer (NK) and CD8+ T 310 
cell cytotoxicity, cytokine secretion by Th1, Th2, and Th17 cells, and modulates programmed 311 
cell death (42). Hence, IL-2 is necessary for the protection against Leishmania in 312 
immunodeficient mice, in which IL-2 restores the activity of SbV (38, 80). The impairment in 313 
IL-2 production is also one of the first functional defects described in untreated HIV-positive 314 
patients and its administration to boost the quantitative and/or qualitative CD4+ T cell 315 
restoration in HIV-infected patients has been evaluated in Phase I, II and III trials (42). These 316 
early results provided evidence that IL-2 therapy combined with existing cART has the 317 
potential to enhance quantitative and qualitative immune restoration, without triggering HIV 318 
replication, even when ART alone had failed to do so. However, restoring CD4+ T cell counts 319 
with IL-2 failed to show long-term clinical benefits in two large Phase III clinical trials, 320 
ESPRIT and SILCAAT (81). IL-2 recipients in the STALWART trial even experienced more 321 
opportunistic infections, death or grade 4 adverse events (AEs) during IL-2 administration, 322 
than those not receiving IL-2 (82).  323 
 324 
To date, no clinical trial for rIL-2 administration in VL patients has been reported. There has 325 
been one case report on the use of rIL-2 in a VL-HIV coinfected patient failing to respond to 326 
anti-leishmanial and HIV treatment with low CD4 counts and incomplete HIV suppression 327 
despite ART use (83). This report indicated no benefit. Importantly, increased Leishmania 328 
parasitemia was observed at each rIL-2 cycle, which might have favored the progression of 329 
HIV infection and possibly explains the reported progressive decline in CD4 T cell count 330 
(83). In a BALB/c mouse model, IL-2 seemed to have a short protective effect against VL 331 
only at the priming phase, without any lasting benefit (84). Such a phase-specific effect could 332 
explain the lack of long-term clinical benefits. In general, the small therapeutic window, 333 
critical dosage with potential high toxicity and challenging treatment conditions suggest IL-2 334 
is an unlikely candidate for boosting immunity in VL-HIV coinfected patients. 335 
3.4. Therapeutic vaccines 336 
Historically, leishmanization (inoculation with live parasites) was shown to have benefit for 337 
protection against re-infection with cutaneous leishmaniasis (CL) and this evidence has driven 338 
the search for an effective vaccine against VL (85).  Besides prophylactic vaccine 339 
development, various approaches employing therapeutic vaccines have been tested 340 
experimentally and clinically; and currently resulted in three licensed vaccines for canine VL 341 
but none for human VL (86). Therapeutic immunization with a first generation vaccine of 342 
aluminum hydroxide precipitated autoclaved L. major (Alum-ALM) + Bacille Calmette-343 
Guérin (BCG) was found clinically effective in CL, mucocutaneous leishmaniasis and 344 
persistent post-kala-azar dermal leishmaniasis (PKDL) cases, with studies progressing to  345 
Phase III clinical trials (87-93), but application to VL has not been reported (62). Similarly, 346 
LeishF1/F2 vaccine (alternatively called Leish-111f) a promising second generation (i.e. 347 
recombinant protein) vaccine for CL, showed insufficient protection against VL in dogs (94). 348 
A modified version of these second generation vaccines, called LeishF3, which 349 
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accommodated changes to enhance its efficacy against VL has been shown to be safe and 350 
immunogenic in a Phase I trial in healthy human volunteers, but therapeutic trials in patients 351 
have not been reported (Table 2) (95). A third generation (i.e. DNA-based), adenovirus 352 
vaccine (ChAd63-KH) was designed to induce Leishmania-specific CD8+ T cells and aimed 353 
at therapeutic use in VL/PKDL patients. It was shown to be safe and immunogenic in healthy 354 
volunteers (96) and is currently in Phase II trial in persistent PKDL patients in Sudan. 355 
 356 
A careful risk-benefit assessment needs to be made when considering therapeutic vaccination 357 
against VL in HIV patients, with depressed immunity. Safety concerns surely exist, but 358 
should not be overstated and should not impede evaluation of therapeutic VL vaccination 359 
studies in virally-suppressed HIV patients as potential benefits can outweigh existing 360 
theoretical risks. In essence, these patients have a higher risk of developing VL and are most 361 
in need of an enhanced immune response upon VL development. Post-marketing trends 362 
suggest that routinely used inactivated (non-VL) vaccines have similar safety profiles among 363 
HIV-uninfected and HIV-infected persons on stable ART (97). Although data are still limited, 364 
HIV-infected individuals who are on ART with well-controlled HIV RNA levels and CD4+ T 365 
cell FRXQWVRI!FHOOV/RUPD\ even receive indicated live-virus vaccines (97). 366 
In addition, modern post cART era studies did not indicate that vaccines are important 367 
triggers of HIV replication or disease progression (98). With regard to efficacy, a highly 368 
immunogenic vaccine will be needed, as well as detailed studies to define the optimal timing 369 
and dosing for vaccination among those with advanced disease. Despite the concerns of 370 
depressed immunity and sparse efficacy data for other types of vaccines, studies have clearly 371 
demonstrated the protective benefit of influenza and Streptococcus pneumoniae vaccinations 372 
even among advanced HIV patients. In summary, these data merit a concurrent evaluation of 373 
therapeutic VL vaccines in coinfected patients who are virologically suppressed at the time of 374 
VL presentation. 375 
4. Promising pipeline immunomodulatory molecules/interventions 376 
While both the pharmacokinetics and pharmacodynamics of a drug, but also the nature of 377 
drug-immune interactions in animals and humans may differ considerably, animal models 378 
may still provide new clues to potential approaches. Here, we selected the most promising 379 
molecules or interventions for their potential in an immunosuppressive environment of the 380 
coinfected individual and refer to recent review papers for a more extensive list (39, 44, 45, 381 
86, 99). The formats discussed below are limited to active immunotherapy attempts including 382 
non-antigen specific strategies such as cytokines that stimulate immunity or suppress the viral 383 
replication; antibodies that block negative regulatory pathways; and indirect 384 
immunomodulation (Figure 2). Antigen-specific strategies such as therapeutic vaccination and 385 
adoptive strategies such as cell therapy are also briefly discussed. Whether the se below listed 386 
molecules listed below could serve as putative targets for human immunotherapy remains to 387 
be demonstrated. 388 
4.1. Non-antigen-specific strategies 389 
The above listed clinical trials with cytokine-adjuvant chemotherapy were based on limited 390 
data from experimental models of VL conducted in the 19¶V. Our knowledge of immune 391 
mechanisms has substantially expanded since thenis time. For instance, IL-12, a pluripotent 392 
cytokine that plays a central role in the initiation/maintenance of Th1 responses and 393 
potentiates T cell IFNȖ production, was shown to have similar effects as IFNȖ in both CL and 394 
VL when injected in mice (64, 100) as well as dogs (101) and human PBMC from treated 395 
Sudanese VL patients (102). Likewise, IL-12 preconditioning of monkeys during acute SIV 396 
infection markedly delayed disease progression (103). While rhIL-12 administration was 397 
well-tolerated and safe, no evidence of improvement in HIV antigen-specific immune 398 
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response could be observed in a Phase I RCT (104). While this suggests that IL-12 therapy is 399 
unlikely to provide major benefits in the chronic phase of an HIV infection, it might still be 400 
valuable in the context of opportunistic infections that are best met with Th1-like effector 401 
immune responses. In line with this, rIL-12 adjuvanted chemotherapy was successfully 402 
evaluated for patients wiWK.DSRVL¶VVDUFRPD(105). In addition, it has been tested as part of a 403 
combination therapy for cryptosporidiosis in two AIDS patients that demonstrated signs of a 404 
brisk immune response and consequently symptomatic improvement, but with severe side 405 
effects that outweighed the clinical benefits (106). Data on the role of IL-12 as an 406 
immunotherapeutic agent or vaccine adjuvant for HIV coinfections could be promising and 407 
merits further research, although potential broad side effects due to its pluripotent role should 408 
be limited (e.g. tissue-targeted delivery, well-timed short boosting approach, etc.). 409 
Unfortunately, the incorporation of IL-12 into larger vaccine trials has lagged, in large 410 
partlargely due to the early setback in a renal carcinoma Phase II trial. However, , even 411 
though the mechanisms underlying the severe acute toxicities that led to two deaths and 12 412 
hospitalizations have been ascribed to an inappropriate dose and administration schedule 413 
(107). 414 
 415 
Like IL-12, many chemokines or cytokines contributing to protection / pathogenesis of VL 416 
are regulated during HIV coinfection. For instance, Th17 cells are highly depleted from the 417 
gut in HIV-infected patients. Recent work in humans has, however, demonstrated the 418 
importance of IL-17 and IL-22 in protection against VL progression from asymptomatic 419 
infection to disease (49). Interestingly, eIn addition, elevated serum IL-27 concentrations 420 
were linked to severity of VL. IL-27 seems to regulate the Th1/Th17 profiles in a L. infantum 421 
mouse model of VL by suppressing the IL-17-induced neutrophil response (108). The IL-27-422 
Th17-IL-17 axis thus seems to be strongly involved in resistance against VL and merits 423 
further therapeutic exploration, especially in HIV coinfected patients with a Th-17-depleted 424 
immune response. 425 
 426 
Despite the central role of IL-7 cytokine therapy in HIV patients in the past, this molecule has 427 
not been evaluated in VL-HIV coinfected patients and remains under-investigated in 428 
experimental models of VL (109). IL-7, like IL-2, has a critical role in peripheral T cell 429 
homeostasis. IL-7 has, however, a more pleiotropic role and was shown to drive CD4+ T cell 430 
restoration in HIV patients, even when HIV replication is controlled. It is also able to promote 431 
Th1 responses, enhance memory T cell expansion (on top of naive T cell response) and 432 
increase CD8+ T cell counts and cytotoxicity in HIV patients (42). Moreover, damage to 433 
hepatocytes during full-blown VL may impair IL-7 production, as IL-7 is also produced by 434 
liver cells in response to inflammation (110). Recombinant IL-7 administration thus has the 435 
potential to safeguard the long-term survival of effector CD4+ T cells in response to persisting 436 
parasites in a VL-HIV coinfection. However, in the ERAMUNE 01 RCT, rIL-7 and dual ART 437 
intensification induced an amplification of the HIV reservoir in well-controlled HIV patients 438 
(111). The authors reasoned that this was the result of the expansion of central memory CD4+ 439 
T cells, carrying HIV DNA, thus limiting this IL-7 based strategy. In the context of VL-HIV 440 
coinfection, this strategy should only be considered if a pronounced clinical benefit to VL 441 
treatment outweighs its potential negative effects. 442 
 443 
Blocking the action of immune-suppressive factors could prove more efficient as it might 444 
allow restoration of protective immunity in a more controlled manner. IL-10 correlates very 445 
well with the parasite load during VL infection. Moreover, in animals, IL-10 blockade (by 446 
means of anti-IL-10R or anti-IL-10 monoclonal antibody) has been proven successful in 447 
lowering parasite burden when combined with conventional treatment in multiple studies in 448 
mice (112, 113). These effects were confirmed in cultures of splenocytes or PBMCs from 449 
Indian and Sudanese VL patients (102, 114). However, in immunodeficient mice treated with 450 
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anti-IL-10R monoclonal antibody, Murray et al. were not only able to show an acceleration of 451 
SbV-associated killing, but alsothey reported a >10-fold SbV dose-sparing effect (115). 452 
Despite the clinical and experimental data suggesting IL-10 as a key target in the 453 
immunopathogenesis of VL, a clinical trial using a monoclonal antibody against IL-10 failed 454 
to start following the decision of the company to stop its production (NCT01437020, 455 
clinicaltrials.gov). 456 
 457 
Increased serum IL-10 concentrations are also observed in HIV-infected patients with disease 458 
progression, in contrast to non-progressing patients where levels were stable (116). In 459 
addition, ART has a clear down-regulating effect on IL-10. On the other hand, increasing 460 
evidence suggests that IL-10 impacts many aspects of HIV pathogenesis, including the 461 
regulation of HIV-specific CD4+ and CD8+ T cell functions, as well as modulation of HIV 462 
replication in PBMC subsets. Genetic polymorphisms in the IL-10 gene promoter that lead to 463 
decreased IL-10 expression have been associated with more rapid disease progression in late 464 
stages of HIV infection, suggesting that the anti-inflammatory effects of IL-10 may be solely 465 
protective in the setting of chronic immune activation and blocking IL-10 function would 466 
only make sense in an acute setting (117). When considering VL-HIV coinfection, these data 467 
would advocate the blocking of excessive IL-10 levels during the acute stage of VL in HIV 468 
patients (in particular pre-ART patients) to allow a beneficial acute response which should 469 
however be time limited to retain the beneficial role of IL-10 in controlling side damage of 470 
chronic HIV and parasitic infections. To reduce the unwanted side effects due to blockage of 471 
normal, and beneficial, biological activities, novel IL-10 signaling inhibitors with for instance 472 
shorter half-lives are first needed (118).  473 
 474 
The concept of immune exhaustion and senescence as a stepwise and progressive loss of T 475 
cell function and proliferative potential, respectively, and evolving to complete T cell 476 
unresponsiveness has been robustly discussed in the context of HIV infection (119). The 477 
driving force is believed to be chronic antigen exposure and consequently extensive non-478 
specific immune activation. Increased immune activation in patients on long-term suppressive 479 
cART has been associated with increased mortality, the occurrence of non-AIDS-defining 480 
conditions, and a poorer recovery in CD4+ T cell count (120, 121). Similarly, increased levels 481 
of Programmed death-ligand 1 (PD-L1) expression on monocytes, B cells and T cells from 482 
untreated HIV patients correlated directly with plasma viral load and inversely with CD4+ T 483 
cell count (122). This mechanism could partly explain the disappointing long-term effects of 484 
IL-2 therapy in HIV patients, as IL-2 was recently shown to upregulate the PD1-PD-L1/L2 485 
pathway (123). While the causative factors of immune exhaustion or senescence are not 486 
completely understood, chronic immune activation, residual HIV-replication and coinfections 487 
are likely main drivers of this process. Recent studies have also focused on the role of this 488 
process in the context of VL and other parasitic infections, showing an accelerated T cell 489 
senescence during VL infection (124). Likewise, a parasite-induced T cell anergy has been 490 
proposed (124). Hence, a modulatory approach to reverse this process or temporarily breaking 491 
the regulatory feedback loop using antibody therapies targeting PD-1, CTLA-4 or its ligands 492 
could prove efficient in coinfected individuals with a potential double-driven T cell 493 
unresponsiveness. Such an approach to reverse the reported T cell unresponsiveness has 494 
proved very effective in experimental VL (57, 125-127).  In SIV-infected rhesus macaques, 495 
anti-PD-1 (in the absence of ART) was shown to enhance virus-specific CD8+ T cell activity, 496 
to reduce viral load and to prolong survival (46). Similarly, anti-PD-L1 antibody therapy 497 
showed promising in a recent Phase I RCT on 6 ART patients, arguing in favor of its potential 498 
use in virologically-suppressed VL-HIV patients (128). Recently, the major HIV cell reservoir 499 
was shown to be composed of PD-1+ CD4+ memory T cells, suggesting an additional positive 500 
effect of anti-PD-1 therapy to combat the concomitant HIV infection (129). 501 
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4.2. Antigen-specific and adoptive strategies 502 
There are multiple studies in which diverse antigens and adjuvants showed promising results 503 
as immunoprophylactic or therapeutic tools in animal models of VL, recently summarized in a 504 
review by Jain and Jain (86). Apart from the current clinically explored strategies and the 505 
safety/efficacy concerns in HIV patients (see above), a promising approach would be to 506 
vaccinate with a non-pathogenic L. tarentolae strain, genetically modified to improve its 507 
immunogenic potential as a live vaccine (130). Likewise, a novel third generation T cell 508 
epitope-enriched DNA vaccine (LEISHDNAVAX) showed significant efficacy when co-509 
administered with a single dose of AmBisome in L donovani-infected mice (131). The 510 
vaccine is based on minimalistic immunogenically defined gene expression (MIDGE) vectors 511 
encoding five conserved antigens developed for efficient induction of Th1 immune responses. 512 
This candidate vaccine has yet to enter clinical Phase I trials.  513 
 514 
Another cutting-edge approach to induce antigen-specific T cell immunity is dendritic cell-515 
based immunotherapy (99, 132). While macrophages are one destination of Leishmania 516 
parasites in the human host, dendritic cells can also harbor parasites, but in addition present 517 
antigen and regulate immune mechanism governing control or progression of infection. 518 
Adoptive transfer of dendritic cells primed with different kinds of Leishmania antigens has 519 
been shown very effective in murine VL, improving both cellular and humoral immunity 520 
(132). Compared to the modest efficacy of immune therapy and therapeutic vaccines against 521 
HIV infection, ex vivo generated dendritic cell therapeutic vaccines aimed at inducing 522 
effective HIV-specific immune responses have yielded the best results in this field (133). The 523 
outcomes of monocyte-derived dendritic cell based therapeutic vaccines still needs 524 
optimization as functional cure was not reached and most patients needed to restart ART, but 525 
this method could provide a strong immunogenic window for concomitant VL-targeted 526 
therapy of coinfected individuals. Due to high costs and required state-of-the-art equipment, 527 
adoptive cell transfer therapy may prove difficult to implement in low-resource settings of 528 
disease endemic countries. 529 
4.3. Indirect strategies 530 
An alternative approach is to indirectly stimulate host immunity to optimize protection against 531 
infection. Such indirect immunomodulators can be obtained by many different types of 532 
substances, including natural products that have immunomodulatory activity. Such  533 
immunomodulators, however, carry the risk of inducing excessive immunopathology and side 534 
effects. Many compounds have been evaluated in VL animal studies over the years, including 535 
CpG oligodeoxynucleotides, acetyl salicylic acid (ASA) and L-arginine (99). Most of these 536 
molecules increase T cell activation through enhanced antigen presentation by costimulation-537 
based therapy or acting on Toll-like receptors (TLRs) (e.g. TLR4/GP29 or MPL; TLR2/Ara-538 
LAM or Pam3Cys). This could be particularly beneficial in HIV coinfected patients, as TLR-539 
agonists such as TLR7 or TLR9 agonists have shown reduction of viral DNA or the viral 540 
reservoir and enhancement of HIV-specific CD8+ T cell immunity in experimental and human 541 
HIV (134, 135). Whether such a multi-TLR targeting approach would benefit human VL-HIV 542 
patients remains unclear and merits further research.  543 
 544 
In a similar manner, it has been suggested that TLR4 and TLR9, two TLRs contributing to the 545 
immune response against Leishmania infection, play a role in the anti-leishmanial mechanism 546 
of miltefosine (136). An alternative strategy, could thus be to concurrently capitalize on the 547 
indirect immunological effects of the combined anti-leishmanial drug in a immuno-548 
chemotherapeutic approach. The relevance and impact of these immunomodulatory actions of 549 
current anti-leishmanials in HIV coinfected VL patients remains to be determined. Besides a 550 
direct mechanism of action, anti-leishmanials can increase nitric oxide and reactive oxygen 551 
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species production due to activation of infected macrophages, leading to elimination of the 552 
parasite. This indirect activation of macrophages has been shown for amphotericin B (137), 553 
miltefosine (138), antimonials (139), and paromomycin (140). Induction of macrophage-554 
derived cytokine release promoting a Th1 response (IL-2, IL-12, IFNȖKDVEHHQQRWHGIRUDOO555 
conventional anti-leishmanials such as amphotericin B (137, 141), miltefosine (138, 141), 556 
paromomycin (141), and sodium stibogluconate (139, 141), even though contradictory results 557 
have been reported, e.g. for miltefosine (142). Related to this, miltefosine restored IFNȖ558 
responsiveness in Leishmania-infected macrophages (138). Another immunostimulatory 559 
property contributing to anti-leishmanial activity is a drug-induced increase in macrophage 560 
membrane fluidity, ameliorating defects in antigen-presentation and enhancing T cell 561 
stimulation. This has been shown after exposure of infected host cells to higher concentrations 562 
of miltefosine, paromomycin and sodium stibogluconate (141). For both antimonials (143) 563 
and miltefosine (144), it has been shown that they increase the phagocytic capacity of 564 
monocytes and macrophages. There are currently no data available whether all these effects 565 
are clinically relevant in terms of short-term treatment response, relapse, final cure, and the 566 
risk of development of PKDL. Despite the current lack of data on clinical relevance, these 567 
background effects should be taken into consideration in future combined 568 
immunochemotherapeutic strategies to incite an effective synergistic effect. The general lack 569 
of response to anti-leishmanial treatment in HIV coinfected patients and the relevance of 570 
concomitant cART for the efficacy of current anti-leishmanials possibly indicate that these 571 
indirect effects are not negligible for a therapeutic response. 572 
5. Concluding Pperspectives 573 
Despite the growing research in immunotherapy against VL (partly reviewed above), no 574 
immunotherapeutic approach has yet been licensed for use in human VL. HIV coinfected 575 
patient groups, in particular, are often excluded from the above described clinical intervention 576 
studies due to the presumed hazards and challenging logistics. Although a vulnerable 577 
population, we would argue that VL-HIV patients should be considered as a relevant target 578 
group for an immunomodulatory approach against VL due to an intensified defect in T cell 579 
immunity, dependence of current anti-leishmanial drugs on the latter, inadequate treatment 580 
outcomes and higher chronicity of the parasitic infection with frequent relapse. In addition, 581 
HIV-targeted immunomodulatory approaches, despite their drawbacks to achieve long-term 582 
functional cure in HIV patients, might find a temporarily window of opportunity in 583 
opportunistic coinfections such as VL, where cART alone is not able to restore protective 584 
immunity. The challenge, however, of immunomodulatory therapy in VL-HIV coinfected 585 
patients is boosting effective VL-specific T cell responses while avoiding activation of latent 586 
provirus and inappropriate immune activation (in virologically-suppressed ART patients) or 587 
HIV recrudescence and increased HIV-susceptibility of target cells (in unstable HIV/AIDS 588 
patients). Clinical studies trials are a necessity to study treatment effects, due to the lack of 589 
good animal or in vitro models mimicking VL-HIV coinfection. 590 
 591 
In Figure 2, we summarized the discussed interventions against VL and highlighted those that 592 
have also been clinically evaluated in the context of HIV. Evidence is lacking to prioritize a 593 
target molecule, but attempts at immunotherapy in VL-HIV patients should best be performed 594 
in ART patients with a recovered immune system. Appropriate adjuvants can be included to 595 
enhance the efficacy of the response, but caution should be taken to avoid excessive and 596 
broad immune activation. The following perspectives are best taken into consideration when 597 
designing or evaluating an immunomodulatory approach in VL-HIV coinfected patients: 598 
 599 
COMBINATION STRATEGIES - As current anti-leishmanial drugs are highly dependent 600 
on host immunity, it is recommended to potentiate chemotherapeutic agents with various 601 
immunomodulators in HIV coinfected patients. While the increment in immunocompetent 602 
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patients could be potentially low, HIV coinfected patients are probably in more need of a 603 
boost in effective T cell immunity against VL to decrease the high mortality and treatment 604 
failure rates typically observedseen in coinfected patients.  605 
 606 
The current clinically explored techniques of single cytokine-adjuvanted therapy in VL have 607 
the inherent danger of a very pluripotent effect in HIV coinfected patients, due to the 608 
intricacies of cytokine networks, and may unpredictably impact the delicate balance between 609 
beneficial VL-specific responses and deleterious immune activation. Future therapeutic use of 610 
broad immunomodulators will most likely lead to unwanted side effects in coinfected patients 611 
until a system-level understanding of their mode of action is available and thus a more 612 
selective and well timed approach can be performed  (145). However, they could potentially 613 
prove valuable as a well-timed adjuvant in a more targeted immunomodulatory approach. 614 
 615 
The other clinically explored strategy in VL is therapeutic vaccination. However, as T cell 616 
senescence and exhaustion could have occurred by persistent HIV replication, further 617 
stimulating effector-memory T cells could be futile or even harmful in VL-HIV patients. 618 
Perhaps a concurrent strategy to reverse this T cell exhaustion (e.g. anti-PD-1 therapy) could 619 
increase vaccine efficacy. It remains to be seen whether VL-based therapeutic vaccines 620 
deployed in HIV coinfected patients are safe and whether a strong enough response can be 621 
induced against VL. In severely CD4+ depleted patients in particular, a concurrent need may 622 
be to first encourage immune reconstitution before vaccination. Combination strategies of 623 
diverse immunomodulators and drugs will thus be crucial in these patients to reach an 624 
effective treatment, perhaps with a more individualized approach. 625 
 626 
STRATIFICATION ± Among patients with tuberculous meningitis, different inflammatory 627 
patterns governed by host genetics are recognized, converging on dysregulated levels of TNF. 628 
At one end of the extreme, a hyper inflammatory phenotype was shown to benefit from 629 
steroid administration; at the other end, where inflammation is inadequate, other immuno-630 
modulatory interventions would be required (146).  In a similar manner, subgroup analyses in 631 
HIV-associated cryptococcal meningitis suggested that the greatest benefit of a short-course 632 
IFNȖ adjuvant therapy was gained among patients with a lack of Cryptococcus-specific 633 
IFNȖ71)&'+ T cell responses (147). In most settings, VL-HIV coinfected individuals will 634 
also be (severely) malnourished upon VL diagnosis, and micro- and macro-nutrient deficiency 635 
can have profound immunological effects. These alterations could critically affect the efficacy 636 
of any immunomodulatory interventions, yet may also provide opportunities for 637 
complementary interventions. We therefore argue that there is a need to assess immune risk 638 
profiles based on functional T cell assays, RNA signatures and other parameters that identify 639 
patients that are more likely to benefit from immune adjuvanted therapy, across the 640 
heterogeneous group of VL-HIV patients.  641 
 642 
TIMING ± VL-HIV coinfection is a dynamic process with diverse stages of infection and 643 
regardless of choice of immunomodulatory intervention, timing will be critical to success. For 644 
instance, high IL-17 levels appeared protective for early VL progression, but its role is still 645 
debatable in chronic infection.  The optimal timing of immunotherapy among HIV coinfected 646 
adults in regard to HIV stage and receipt of antiretroviral therapy also remain important 647 
unanswered questions. Most benefit is probably to be gained in early stages of HIV infection 648 
as well as in under-therapy suppressed patients, who are able to effectively respond to 649 
immunomodulators. Therefore, we would argue for a primary evaluation of novel approaches 650 
in stable ART patients that have a somewhat reconstituted CD4+ T cell immunity and 651 
suppressed viral load, including frequent monitoring of blips in viral load and CD4+ T cell  652 
count. It remains to be investigated whether HIV patients with a severe suppression in T cell 653 
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immunity are also able to respond to immune stimulators or whether virological suppression 654 
first has to be prioritized to enable T cell responsiveness. 655 
 656 
TARGETED STRATEGIES ± The delivery system is also an important part of an immune 657 
based strategy and implementation of various novel approaches based on liposomes, 658 
electroporation, dendrimers, carbon nanotubes etc. can boost efficacy (86). For instance, as an 659 
alternative for broad cytokine adjuvants, more effective and tolerable approaches are being 660 
explored like encapsulation in micro or nanoparticles, restricting the delivery to APCs and/or 661 
the co-delivery with another immunomodulatory molecule via transducing vectors. Similar 662 
techniques such as microRNA or small interference RNA based therapy could be explored, 663 
but these novel drugs will be most likely unaffordable in most countries where the disease is 664 
endemic. 665 
 666 
ACCESIBILITY ± The target population is largely living in very rural and/or poor areas, 667 
where a highly controlled clinical trial setting can be challenging and costly to implement. It 668 
will be imperative to strengthen human and infrastructural capacity in disease endemic areas 669 
to ensure a sustainable base for immunotherapeutic research and to assess safety and efficacy 670 
of novel interventions. Moreover, designed therapeutics should become affordable and 671 
accessible to the patient population, suggesting innovative low-resource-demanding methods 672 
ideally without the need of a cold chain. 673 
 674 
 675 
CONCLUSION - To advance the development of immunomodulatory approaches for VL-676 
HIV coinfection, a more detailed account of the immunological status induced by the 677 
coinfection and surrogate markers of cure and protection are still required, as a forerunner to 678 
inclusion of such patients in clinical intervention studies. The main limitation for 679 
comprehensive immunological research is, however, the need for human samples of 680 
longitudinal studies and trials in (often very remote) low-resource settings. With more 681 
research aimed at discovering key synergistic pathways of immune cell cross-talk and 682 
renewed efforts to translate these findings into effective treatment modalities that target 683 
Leishmania without promoting HIV replication, the goal of improved patient outcome and 684 
clinical management of this neglected population may be achievable. 685 
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Figures and Tables 
Table 1. The main drugs currently used for treatment of visceral leishmaniasis, adapted from 
(5) 
Drug Toxicity 
 
Main limitations 
Pentavalent 
Antimonials (SbV) 
Frequent, potentially 
severe 
Toxicity (high mortality in HIV 
      coinfected African patients) 
- Pancreatitis Painful injection (im) 
- Cardiotoxicity Length of treatment 
- Nephrotoxicity Resistance in India 
- Hepatotoxicity  
Conventional 
Amphotericin B 
deoxycholate 
Frequent infusion-related     
reactions 
Lengthy hospitalization (in-patient care) 
- Nephrotoxicity Slow iv infusion 
- hypokalemia Nephrotoxicity 
Liposomal 
Amphotericin B 
(AmBisome) 
Uncommon and mild High price 
- Nephrotoxicity 
(limited) 
Slow iv infusion 
Heat instability (<25° C) 
 Accessibility 
 Single dose not effective in East Africa 
Miltefosine Common, usually mild 
and transient  
Relatively limited efficacy data in East  
     Africa 
 - Gastro-intestinal Possibly teratogenic 
 - Hepatotoxicity Potential for resistanceb 
  Patient compliance (oral drug) 
  High price 
Paromomycin 
Sulphate 
(aminosidine) 
Common Toxicity (Oto- and nephrotoxicity) 
- Ototoxicity Resistance readily obtained in lab  
      isolates - Nephrotoxicity 
- Hepatotoxicity Efficacy variable between and within  
      regions (less in Sudan) 
Pentamidine Common Low efficacy 
- Gastro-intestinal Toxicity (diabetes, renal failure) 
- Cardiotoxicity Length of treatment 
- Pancreatitis  
- (iIr)reversible 
diabetes mellitus 
 
b Due to long half-life +  low genetic barrier (resistance readily obtained in lab isolates) 
iv: intravenous injection; im: intramuscular injection 
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Table 2. Published clinical reports on the use of immuno(chemo)therapy against VL and VL-HIV 
Ref Country; 
year; 
design 
Patient characteristics Chemo agent Immuno agent Outcome (EOT) Comments 
 VISCERAL LEISHMANIASIS MONO-INFECTION  
(148
) 
Brazil; 
1990; 
case series 
[1] SSG-unresponsive VL (n=8);  
<18 years (8/8);  
Mean age: 6.5 years 
SSG 20 mg/kg  IFNȖ  
(100-400 µg/m2 
for 10-40 days) 
6/8 cured EOT (75%) 
No relapse during study 
period 
Higher cure rates in both groups 
compared  to historical controls 
Tolerability acceptable (fever) 
   
[2] Severely ill primary VL 
(n=9) 
<18 years (8/9)  
Mean age: 9.8 years 
 
SSG 20 mg/kg 
 
IFNȖ  
(100-400 µg/m2 
for 10-40 days) 
 
8/9 cured EOT (89%) 
No relapse during study 
period 
(149
) 
Brazil, 
1993;  
case series 
[1] Primary VL (n=8) 
Predominantly children  
Median age: 5 years 
 
 
[2] SSG-unresponsive refractory 
VL (n=14)  
Median age: 4 years 
SSG 20 mg/kg  
 
 
 
 
SSG 20 mg/kg 
 
IFNȖ 
(100-400 µg/m2 
for 10-40 days) 
 
8/8 cured EOT 
Cure 12M: 8/8 (100%) 
1/8 relapsed 
12/14 cured 
 
Cure 12M: 9/14 (64%) 
6/12 relapsed 
Both groups: more severe cases than in 
1990 
   
IFNȖ  
(100-400 µg/m2 
for 10-40 days) 
 
(150
) 
Kenya; 
1993; 
RCT 
[1] Primary VL (n=10) 
<18 years: 7/10 
 
 
 
 
[2] Primary VL (n=14) 
<18 years: 11/14 
SSG 20 mg/kg  
 
 
 
 
 
SSG 20mg/kg 
IFNȖ  
(100 µg/m2  every 
two days - 30 
days) 
 
 
 
/ 
24/24 cured EOT 
Week 1: 50% cured 
Week 2: 75% cured 
Week 4: 100% cured 
 
Week 1: 22% cured 
Week 2: 58% cured 
Week 4: 88% cured 
Control  group included 
 
no relapse cases 
 
a non-significant accelerated response 
with SSG + IFNy 
(73) Brazil; 
1994;  
RCT 
[1] 10 neutropenic primary VL 
 
 
[2] 10 neutropenic primary VL 
SSG 10-20 mg/kg for 
10 days 
 
SSG 10-20 mg/kg for 
10 days 
GM-CSF 
(5mg/kg for 10 
days) 
 
Placebo 
Cure M3: 100% 
 
 
Cure M3: 100% 
Study focused on hematological 
evaluation and secondary infections 
 
Secondary infections occurred in 3 
GM-CSF and in 8 placebo recipients 
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(151
) 
India; 
1995;  
RCT 
[1] Primary VL (n=16) 
Mean age 21 years (range 6-52) 
 
SSG 20 mg/kg for 20-
30 days 
IFNȖ  
(100 µg/m2) 
Cure D10: 10/15 (63%) 
Cure D20: 14/15 (93%) 
Cure D30: 15/15 (100%) 
Cure M6: 13/15 (87%) 
 
D10 and D20 difference statistically 
significant 
 
No relapse up to M24 
  [2] Primary VL (n=15) 
Mean age 27 years (range 5-58) 
SSG 20 mg/kg for 20-
30 days 
/ Cure D10: 1/15 (7%) 
Cure D20: 6/15 (40%) 
Cure D30: 11/15 (73%) 
Cure M6: 9/15 (60%) 
Treatment was discontinued early in 
the 14 IFNȖ treated responders after 
D20 
 
(65) India,  
1997 
 [1] Primary VL (n=52) 
Mean age 20 years; 60% male 
 
 
[2] Primary VL (n=52) 
Mean age 18 years; 58% male 
 
 
[3] Primary VL (n=52) 
Mean age 20 years; 69% male 
SSG 20 mg/kg for 30 
days 
 
 
SSG 20 mg/kg for 30 
days 
 
 
SSG 20 mg/kg for 30 
days 
IFNȖ  
(100 µg/m2 for 30 
days) 
 
 
IFNȖ  
(100 µg/m2 for 15 
days) 
 
 
/ 
Cure (EOT): 25/47 
Relapse: 1 
6M cure: 24/49 (49%) 
 
Cure (EOT): 22/50 
Relapse: 1 
6M: 21/50 (42%) 
 
Cure (EOT): 20/48 
Relapse: 2 
6M cure: 18/50 (36%) 
High failure rate with standard therapy 
(SSG-resistance?) 
 
 Differences not statistically significant 
(95) USA,  
2012, 
Phase I 
RCT 
[1] Healthy volunteers (n=12) 
 
 
[2] Healthy volunteers (n=12) 
 
 
[3] Healthy volunteers (n=12) 
 
/ 
 
 
/ 
 
 
/ 
Leish F3 (20ug) 
+ GLA-SE (5ug) 
 
Leish F3 (20ug) 
+ GLA-SE (2ug) 
 
Leish F3 (20ug) 
Safe and immunogenic D84: 
10/10 
 
Safe and immunogenic D84: 
8/8 
 
Safe and immunogenic D84: 
9/9 
Subunit vaccine: single recombinant 
fusion protein of 2 preserved proteins 
 
 
(96) UK, 
2016, 
Phase I 
trial 
[1] Healthy volunteers (n=20] 
n=5 low dose 
n=15 high dose 
/ Ch1d63-KH 
(1x1010 vp or 
7.5x1010 vp) 
Safe and immunogenic D90: 
20/20 
Adenovirus vector encoding 2 
Leishmania proteins 
 
Dose escalation study 
 HIV & VISCERAL LEISHMANIASIS COINFECTION  
(68) CASE 
REPORT; 
1990 
Full blown AIDS patient with 
recurrent VL 
19y old Algerian male 
Meglumine 
antimoniate (dose 
unkown) 
IFNȖ (175 µg/d iv 
or sc for 21 days) 
 
1 relapse treated 
Resistance to antimoniate 
 
 
In revi
ew
Pentamidine (2 mg/kg 
iv 3 times/w, 1w/mo) 
IFNȖ (175 µg/d 
sc 3 times/w, 
1w/mo) 
3 relapses treated 
Cure 6M: Only two mild 
relapses with minimal adverse 
events 
(67) CASE 
REPORT; 
1993 
Three full blown AIDS patients Meglumine 
antimoniate (dose 
unknown) 
IFNȖ (dose 
unknown) 
Clinical improvement 
Reduction in parasite burden 
 
(70) CASE 
REPORT; 
1994 
Full blown AIDS patient with 
KS 
40y old German male 
SSG (dose unknown) IFNȖ (dose 
unknown) 
Aggravated Kaposi syndrome 
(KS) 
 
(79) CASE 
REPORT; 
2004 
Primary VL 
37y old Italian male 
CD4 <50 mcl 
On ART 
Amphotericin B 
(4mg/kg for 5 days + 5 
non-consequent days) 
GM-CSF 
(150 mcg/twice a 
week for 12 
weeks) 
Dramatic Clinical 
improvement 
 
No adverse event 
 
(83) CASE 
REPORT; 
2007 
Unresponsive VL 
36y old Italian woman 
CD4: 98 cells/µl 
On ART 
Amphotericin B 
(between every cycle) 
IL-2 (twice/day 
for 5 days ± 
7cycles every 4-8 
weeks (cycle 1-4: 
3MIU; cycle 5-7: 
6MIU) 
No benefit 
 
Increase in Leishmania DNA 
 
IFN: interferon; SSG: sodium stibogluconate; VL: visceral leishmaniasis; EOT: End of Treatment: M: month 
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 Figure 1: Current views on synergistic mechanisms in T cell immunity against VL due to 
HIV coinfection inciting persistent viral and parasite replication in VL-HIV coinfected 
patients.  
APC: antigen presenting cell; Th: T-helper; GALT: gut- associated lymphoid tissue; CTL: 
cytotoxic T cell; IL: Interleukin; ART: antiretroviral therapy; IFN: interferon; LPS: 
lipopolysaccharide; TNF: Tumor necrosis factor 
 
Figure 2: Overview of described clinical and preclinical immunomodulatory interventions in 
human visceral leishmaniasis and their application in (VL)-HIV (co)infection.  
IL: interleukin; IFN: interferon; PD-(L)1: programmed cell death-(ligand)1; GM-CSF: 
Granulocyte macrophage colony stimulating factor; CTLA: Cytotoxic T lymphocyte-
associated molecule; CD: Cluster of differentiation ; BCG: Bacillus Calmette-Guérin; Alu-
ALM: aluminum hydroxide precipitated autoclaved L. major; DC: dendritic cell; GP: 
Glycoprotein; Ara-LAM: Arabinosylated lipoarabinomannan; Pam3Cys: synthetic bacterial 
lipopeptide; CpG Odn: CpG oligodeoxynucleotides; ASA: Acetyl Salicylic Acid; MPL: 
monophosphoryl lipid  
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